Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Mitsubishi Tanabe Plans Scaled Entry Into U.S. Market

This article was originally published in PharmAsia News

Executive Summary

Mitsubishi Tanabe Pharma has plans to enter the U.S. pharmaceutical market in two years, beginning with a pair of drugs to treat kidney problems. To market the drugs, Mitsubishi Tanabe also plans to set up a U.S.-based sales unit and hire 100 representatives. The company expects to apply next year for U.S. approval of a hyperphosphatemia drug to treat kidney dysfunction as its first product. A year later, it plans to file for a treatment for chronic kidney failure with the hope of launching both drugs in 2012 or 2013. Longer-range plans call for introducing a diabetes treatment, along with entering into marketing agreements and acquiring U.S. companies. (Click here for more - a subscription may be required

You may also be interested in...

Orphan Exclusivity: Rarely Used, But Well-Known, Loophole Would Be Closed By House Legislation

US FDA could revoke orphan designation or exclusivity if cost recovery requirements were not satisfied under bill unanimously passed by the House Energy and Commerce Committee.

How The US FDA Finds Pre-Approval Inspection Alternatives During COVID-19 Pandemic

Officials explain how remote record reviews, site transfers and other factors can green-light approvals of drugs and biologics.

10 Non-COVID News Updates To Listen For In Second Quarter Reporting

The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts